UNSPSC 51181578: Dapagliflozin

Dapagliflozin is a medication used to treat type 2 diabetes and, with certain restrictions, type 1 diabetes. It is also used to treat adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure

UNSPSC 51181578 Dapagliflozin, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally covers a specific pharmaceutical active ingredient—dapagliflozin, a SGLT2 inhibitor used primarily in diabetes and heart-failure treatment—yet the recent opportunities block contains no direct solicitations for dapagliflozin itself. Instead, the tagged opportunities span pharmacy services contracting, emergency medical supplies procurement, naloxone distribution, forensic drug standards, and pharmaceutical group purchasing organization memberships, none of which explicitly reference dapagliflozin or narrow-spectrum pharmaceutical commodity purchasing by dose, formulation, or active ingredient.

The opportunities that do touch pharmaceutical procurement—Dane County's RFP for comprehensive pharmacy services to a long-term care facility (response due October 22, 2026), Tucson Fire's RFP for BLS/ALS pharmaceuticals and vending systems (response deadline passed June 24, 2026), and West Texas Centers' RFP for prescription pharmacy services across 35 sites in 23 counties (response due August 21, 2026)—all structure purchasing through formulary management, dispensing services, and markup-based reimbursement rather than unit procurement of specific active pharmaceutical ingredients. No issuing body has solicited dapagliflozin as a standalone line item or by UNSPSC commodity code. The mismatch between the code's specificity and the actual buying patterns visible in recent state and local notices suggests either that jurisdictions source this pharmaceutical through broader group purchasing agreements or that procurement systems have tagged opportunities incorrectly. This code shows little actionable current opportunity for direct commodity suppliers.